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Abstract
Background: Stromal cell-derived factor-1 (SDF1) and its receptor CXC chemokine receptor 4 (CXCR4) play a critical role in
progenitor cell homing, mobilization and differentiation. It would be interesting to assess the predictive value of SDF-1alpha
level for EPC number, and to ascertain whether there is a relationship between SDF1 gene variation, plasma SDF-1alpha
level, and the number and function of circulating EPCs. We also tested whether EPC number and function was related to
CXCR4 gene variation.
Methodology and Principal Findings: We genotyped a cohort of individuals who participated in the Bruneck Study for
single nucleotide polymorphisms (SNPs) in the SDF1 and CXCR4 genes, and measured blood SDF1a level as well as EPC
number and function. SDF1a levels were correlated with age, gender, alcohol consumption, circulating reticulocyte
numbers, and concentrations of matrix metalloproteinase-9, C-reactive protein, cystatin C, fibrinogen and homocytein. In
blood samples taken in 2005, EPC number was inversely associated with SDF1a level (p,0.001). EPC number in 2005 was
also inversely associated with SDF1a level in 2000 (p=0.009), suggesting a predictive value of plasma SDF1a level for EPC
number. There was an association between the SDF1 gene rs2297630 SNP A/A genotype, increased SDF1a level (p=0.002)
and lower EPC number (p=0.006).
Conclusions: Our data indicate that a SDF1 gene variation (rs2297630) has an influence on SDF1a level and circulating EPC
number, and that plasma SDF1a level is a predictor of EPC number.
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Introduction
Asahara and colleagues in 1997 demonstrated for the first time
that purified CD34 positive haematopoietic progenitor cells from
peripheral blood could differentiate, ex-vivo, into an endothelial
phenotype and were named Endothelial Progenitor Cells
(EPCs)[1]. Growing evidence indicates that EPCs play a major
role in angiogenesis and vasculogenesis[2,3]. Indeed, mobilized
EPCs can promote new blood vessel formation in ischaemic
tissues, enhancing perfusion and recovery[2,3]. Ex vivo expanded
EPCs isolated from peripheral blood can also incorporate into the
site of myocardial neovascularization[4], and intracoronary
infusion of peripheral blood or bone marrow-derived progenitors
in patients with acute myocardial infarction was shown to
significantly enhance post-infarction remodelling[5,6]. Moreover,
EPC numbers have a prognostic value and can be used as a
predictive biomarker in the cardiovascular diseases[7–9]. Other
investigators have also shown reduced EPC number in patients
with risk factors for cardiovascular diseases such as diabetes[10,11]
and smoking[12], with cessation of smoking resulting in a return of
EPC numbers to normal. EPC number is also reduced in groups of
patients known to be at higher risk of cardiovascular disease such
as those with rheumatoid arthritis[13] or chronic renal failure[14].
EPC number is also known to be reduced in established non-
coronary cardiovascular disorders such as in patients with
strokes[15], peripheral vascular disease[10] and patients with
erectile dysfunction[16]. However, our recent data from a
population-based, longitudinal study refuted the traditional view
that the EPC number is negatively related to cardiovascular risk
factors. We showed that changes of EPC numbers are loosely
associated with certain risk factors for the cardiovascular disease
and not directly associate with the disease development[17].
Animal studies have indicated that SDF1 (also known as CXC
chemokine ligans 12) and its receptor CXC chemokine receptor 4
(CXCR4) plays a critical role in progenitor cell homing,
mobilization and differentiation. Inactivation of the SDF1 or
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abnormality in the cerebellar and gastrointestinal vasculature and
in hematopoiesis development[18–20]. The number of circulating
hematopoietic stem cells (HSCs) or EPCs were increased by SDF1
gene transfer using the adenovirus infection technique[21–23].
Overexpression of SDF1 in ischemic tissues has been found to
enhance EPC recruitment from peripheral blood and to induce
neoangiogenesis in ischemic tissues[24,25]. Recent evidence also
suggests that SDF1a is a driving force for EPC differentiation[26].
All these findings from animal studies strongly suggest that SDF1a
has a crucial role in stem/progenitor cell mobilization, differen-
tiation, and injured tissues-specific homing. However, it remained
unknown whether SDF1a played such a role in humans.
Therefore, we recently examined the levels of SDF1a and several
angiogenic cytokines in relation to circulating EPC numbers in a
population-based study. We found that plasma levels of SDF1a,
but not VEGF or G-CSF, were strongly associated with EPC
number and function, suggesting a role of SDF1a in EPC
mobilization and differentiation in humans[17]. In that study, the
association of SDF1a levels with EPC numbers was detected using
blood samples taken at the same time point. In the present study,
we investigated whether SDF1a levels had a long-term predictive
value for EPC numbers.
There is emerging evidence indicating that variation in the
human SDF1 gene can have an influence on SDF1a levels[27,28],
which was demonstrated clearly to be involved in progenitor cell
mobilization and differentiation in human and animal studies.
Moreover, previous study showed that EPC number is, at least in
part, genetically regulated[29], and the presence of SDF1-3’A
allele was a predictive factor of CD34
+ cell mobilization[30],
which prompt us to hypothesize that the SDF-1 gene single-
nucleotide polymorphism (SNP) might involve in their gene
transcription and progenitor cell mobilization, differentiation and
homing. In the present study, we examined whether there was a
relationship between SDF1 gene variation, SDF1a level and
circulating EPC number. In addition, we tested whether there was
also a relationship between variation in the gene encoding the
SDF1a receptor CXCR4 and EPC number.
Methods
Study Population and clinical variables
The subjectsofthis studywereresidentsof the Bruneckarea inthe
Bolzano Province of Italy, who participated in the Bruneck
Study[31]. Details of the Bruneck study have been described
previously[31]. DNA samples were available for 826 subjects, and
these were genotyped single nucleotide polymorphisms (SNPs) in the
SDF1 and CXCR4 genes. Blood samples taken in 2000 (n=684) and
2005 (n=574) respectively were used for measurements of SDF1a
levels. EPC number and function were assessed in blood samples
collected in 2005 (n=571 for EPC number and n=542 for EPC
colonies number respectively). Subjects with and those without EPC
number and EPC function assessments did not differ in age, sex and
cardiovascular risk factors. The appropriate ethics committees
(Autonome Provinz Bozen-Sanitatsbetrieb Bozen Ethikkomittee)
approved the study protocol and all study subjects gave their written
informed consent before entering the study.
Systolic and diastolic blood pressure was taken with a standard
mercury sphygmomanometer after at least 10 min of rest (mean of
three independent measurements). Hypertension was defined as
blood pressure $140/90 mm Hg or the use of anti-hypertensive
drugs. The average number of cigarettes smoked per day was
noted for each smoker and ex-smoker. Diabetes was diagnosed
according to ADA criteria. Assessment of regular alcohol
consumption was performed with a standardized questionnaireand
quantified in terms of grams per day (g/day).
EPC culture assay
EPC numbers in the blood samples were determined as
described previously[17]. Briefly, positive stained cells for DiI-
Ac-LDL and Lectin were considered to be EPCs on day 5 of
culture. The total numbers of EPC per well were counted by two
trained independent senior investigators blinded to the clinical
details of the subjects. The EPC in a minimum of two wells were
counted and the average was then recorded.
EPC-colony formation unit (CFU) assay
The EPC-CFU assay performed as described previously[17].
Briefly, PBMNC were resuspended in EPC culture medium
(M199 with 20%FCS and antibiotics) and then plated on
fibronectin coated 6 well plates at a concentration of 5 million
cells per well. The endothelial colonies were counted manually on
day 7. Strict guidelines were followed to ensure consistent counting
of EPC colonies. Two senior investigators who were blinded to the
subjects’ clinical status counted the colonies.
Enzyme-linked immunosorbent assay (ELISA)
Commercially available SDF1a and matrix metalloproteinase-9
(MMP9) ELISA kits (Quantikine, R&D Systems, UK) were used to
determine plasma SDF1a and MMP9 levels. All ELISA tests were
carried out at room temperature on freshly thawed plasma
samples. The concentration was determined by comparison with a
standard curve, following manufacturer’s instruction. Other
laboratory parameters and vascular risk factors were all examined
by standard methods[32].
Genotype analyses
We selected tagging SNPs in the SDF1 and CXCR4 genes from
the HapMap database (data release in June 2005). Three SNPs in
SDF1 (rs2297630, rs266087 and rs1413519) and two in CXCR4
(rs16832740 and rs12691874) to capture SNPs with a minor allele
frequency .0.2 at these loci and R
2.0.8 were typed in this study.
In addition, we studied the rs266085 SNP which had been
reported to influence SDF1 expression[27] and the rs1801157
SNP which had suggested to be associated with plasma SDF1
level[28]. Genomic DNA was extracted from blood samples of the
Bruneck study subjects, and genotypes were determined using the
TaqMan genotyping method.
Statistical Analysis
The data were analyzed using the SPSS 15.0 and BMDP
software packages. Continuous variables were presented as
means6SD or medians (interquartile range), and dichotomous
variables as percentages. Correlations between EPC number and
EPC-CFU, SDF1a level and other parameters were estimated by
calculation of crude and partial (age/sex-corrected) Pearson
correlation coefficients. Variables with a skewed distribution were
logBeB-transformed. Non-parametric tests yielded very similar
findings (data not presented). Associations of EPC number, EPC-
CFU and SDF1a level with SDF1 and CXCR4 genotypes were
assessed using generalized linear models adjusted for age and sex.
Multivariate models additionally included standard cardiovascular
risk factors and the factors associated with SDF1a levels (LDL and
HDL cholesterol concentrations, smoking, hypertension, diabetes,
alcohol consumption, and levels of CRP, MMP9, cystatin C,
fibrinogen and homocystein). A Bonferroni correction was
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SDF1 and 2 in CXCR4) performed.
Results
Relationship of plasma SDF1a level with inflammatory
markers and other variables
Near normal distribution of SDF1a was observed in our study
(Figure 1A. Kolmogorov-Smirnov p.0.05). Mean SDF1a levels
in 2000 and 2005 were 2652 pg/ml and 2565 pg/ml, with a range
of 880 pg/ml to 5595 pg/ml and 1322 pg/ml to 4174 pg/ml,
respectively. SDF1a levels in 2000 and 2005 were highly
correlated (intraclass correlation=0.495; P,0.001), indicating
that the SDF1a level is relatively consistent over time. As
expected, both plasma SDF1a level measured in 2000 (r=0.207,
p,0.001) and 2005 (r=0.270, p,0.001) increased with age
(Figure 1B) and was higher in women (2619 in women vs. 2497
in men, p=0.002). Moreover, plasma SDF1a level was correlated
with alcohol consumption (age/sex-adjusted correlation coefficient
r=20.087, p=0.042), reticulocyte numbers (r=20.132,
p=0.002), plasma levels of matrix metalloproteinase-9 (MMP9)
(r=0.146, p=0.001), C-reactive protein (hsCRP) (r=0.090,
p=0.037), cystatin C (r=0.277, p,0.001), fibrinogen (r=0.159,
p,0.001), and homocytein (r=0.174, p=0.001). (Table 1)
Plasma SDF1a level predicts EPC number
EPC number andEPC-CFU number (per1 mlblood)displayed a
non-normal distribution, with the majority of subjects (more than
75%) having 0 to 1000 EPC and 0 to 340 EPC-CFU, respectively.
SDF1a levels were significantly and inversely associated with EPC
number (p,0.001) in samples collected in 2005 (Figure 1C),
indicating that SDF1a has an influence on EPC number in the
general population. Importantly, EPC number in 2005 was also
associated with SDF1a level in 2000 (p=0.009), indicating a long-
term predictive value of SDF1a level for circulating EPC number
(Figure 1D). No association between SDF1a level and EPC
function measured by EPC-CFU was detected in this study.
Association of SDF1 genotyping, plasma SDF1a level and
circulating EPC number
Allele and genotype frequencies of the SDF1 and CXCR4 SNPs
examined in this study are shown in Table 2. The genotype
distributions were consistent with Hardy-Weinberg equilibrium.
The SDF1 rs2297630 SNP was associated with plasma SDF1a
level (p=0.002) and circulating EPC number (p=0.006), with the
A/A genotype associating with higher SDF1a level and lower EPC
number (Figure 2 & Table 3). These associations remained
significant after Bonferroni correction for the number of SNPs tested
(Bonferroni corrected p=0.014 and p=0.042, respectively). The
associations also remained significant after adjusting for cardiovas-
cular risk factors and the factors that were associated with SDF1a
levels,includingLDLandHDLcholesterolconcentrations,smoking,
hypertension, diabetes, alcohol consumption, and levels of hsCRP,
MMP9, cystatin C, fibrinogen and homocystein (Table 3).
Plasma SDF1a level and circulating EPC number was not
associated with the other SDF1 or CXCR4 SNPs tested. No
association was observed between any of the SNPs tested and
EPC-CFU.
Discussion
The population-based, longitudinal design of the Bruneck study
allowed us to investigate the relationships between SDF1a levels at
two different time points (2000 and 2005) and the relationships of
the SDF1a levels at these different time points with circulating
EPC numbers. A key finding from our study is the high degree of
correlation the two SDF1a measurements in blood samples taken
in 2000 and 2005 respectively, suggesting that although SDF1a
levels are correlated with cardiovascular risk factors, the levels in
an individual are relatively consistent over time. In addition, the
study revealed an association between SDF1a level in 2000 and
EPC number in 2005, suggesting a long-term predictive value of
SDF1a level for EPC number. Another important, novel finding of
this study is that there is an association between variation in the
SDF1 gene, SDF1a level and EPC number, indicating that the
inter-individual variability in SDF1a level and EPC number is
influenced by variation in the SDF1 gene.
SDF1 is a member of the chemokine CXC subfamily originally
isolated from murine bone marrow stromal cells and is expressed
also by stromal cells of various tissues[33]. Animal studies have
shown that increasing SDF expression by adenovirus gene transfer
can induce EPC mobilization from bone marrow into the
peripheral blood, thereby increasing circulating EPC num-
bers[21–23], enhancing angiogenesis and blood perfusion in
ischemic tissues[25]. These studies have led to the hypothesis that
SDF1 plays an important role in EPC mobilization, differentiation
and homing. However, data from our study showed that SDF-1a
levels were inversely, rather than positively, associated with
circulating EPC numbers. There are several possible explanations.
Almost all of the exiting data that suggest that SDF1a can induce
circulating EPCs are from studies in mouse, and the situations in
humans may be different and more complex. Indeed, a number of
studies including the present study have shown that EPC numbers
in humans are related to a number of factors including age,
gender, smoking, lipid levels, hypertension, diabetes, etc. Second-
ly, it is possible that the relationship of SDF1 with EPC
mobilization, differentiation and homing in the acute phase is
different from that in the normal situation. Studies of mouse
ischemia models showed that the number of c-Kit
+ cells in
peripheral blood was lower but the level of SDF1a was much
higher at 14 days after ischemia, as compared with control
mice[26], suggesting that EPCs are mobilized into peripheral
blood from bone marrow after the onset of ischemia, but at a later
stage, the numbers of mobilized EPC in peripheral blood decrease
due to their homing to the ischemic site. Thirdly, because SDF1a
functions as a chemoattractant for stem/progenitor cells, the
SDF1a gradient between bone marrow, peripheral blood and
injured tissue/sites is crucial for stem/progenitor cell mobilization,
differentiation and homing[26,34–36]. It has been reported that
stem/progenitor cells in bone marrow and peripheral blood are
mobilized and homed to the ischemic or injured tissue due to high
SDF1a levels in the ischemic or injured tissue[26] and lower levels
of SDF-1a in the bone marrow[37]. Measurement of plasma
SDF1a level does not represent the gradient mention above, and
therefore, the inverse relationship between plasma SDF1a level
and circulating EPC number should not be interpreted as in
conflict with the notion that SDF1 plays an important role in EPC
mobilization, differentiation and homing.
A recent study showed that there is significant correlation in the
number of circulating EPCs between parents and their offsprings,
leading to the hypothesis that EPC number is, at least in part,
genetically regulated[29]. The results of our study support this
hypothesis and indicate that such a genetic influence is likely in
part due to variation in the SDF1 gene. In particular, we found
that SDF1a level and circulating EPC number are associated with
the SDF1 gene rs2297630 SNP in the Bruneck study cohort. A
potential interpretation for this novel finding is that variation in
the SDF1 gene can influence EPC number via an effect on the
SDF1 Gene Variation and EPC
PLoS ONE | www.plosone.org 3 December 2008 | Volume 3 | Issue 12 | e4061Figure 1. Panel A shows near normal distribution of SDF1a in the Bruncek study population. Panel B displays the association between SDF-1a
measured in 2000 and in 2005 and age (r=0.270, p,0.001). Panel C illustrates the correlation between SDF1a levels and EPC number in 2005. The
regression line demonstrates clearly that SDF1a levels are inverse association with EPC number. Panel D illustrates the association between EPC
numbers in 2005 and SDF1a level in 2000 (tertile groups). SDF-1 tertile groups are defined as follows: T1,2409, T2 2409–2753 and T3.2753. The box
plots indicating EPC number median and IQRs. Notably, EPC numbers are significant associated inversely with SDF-1a levels, especially much low EPC
number were likely observed in the top tertile group of SDF-1 levels.
doi:10.1371/journal.pone.0004061.g001
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SDF1 gene. It is possible that the association of this SNP with
SDF1a level and circulating EPC number has arisen from a direct
functional effect of this SNP on SDF1 expression or mRNA
splicing. Alternatively, the rs2297630 SNP might be a functionally
neutral marker that is in linkage disequilibrium with a functional
polymorphism located elsewhere at the SDF1 locus.
Two other SDF1 SNPs, rs266085 and rs1801157, have been
reported to beassociated with SDF1levels[27,28]and the latter SNP
has also been reported to be associated with CD34
+ cell
mobilization[30]. Some, but not all, studies have suggested that
the rs1801157 SNP is associated with HIV infection and AIDS[38–
40] and there is also evidence suggesting that this SNP is associated
Table 3. Plasma SDF1a levels and circulating EPC numbers
according to SDF1 and CXCR4 SNP genotypes.
SNP Genotype SDF1a level
P
value EPC number
P
value
SDF1
rs2297630
GG 2562 (2515–2609) 0.002 382 (336–434) 0.006
AG 2524 (2461–2586) (0.002) 409 (344–486) (0.015)
AA 2863 (2684–3043) 175 (107–286)
SDF1
rs266085
GG 2572 (2512–2631) 0.661 354 (300–417) 0.793
AG 2539 (2480–2597) (0.328) 383 (326–449) (0.866)
AA 2529 (2431–2626) 362 (277–473)
SDF1
rs266087
GG 2570 (2510–2630) 0.931 355 (302–418) 0.702
AG 2574 (2519–2630) (0.742) 391 (336–455) (0.803)
AA 2552 (2450–2654) 378 (286–499)
SDF1
rs1801157
GG 2592 (2544–2641) 0.260 370 (323–425) 0.998
AG 2547 (2483–2612) (0.208) 368 (307–441) (0.931)
AA 2467 (2295–2638) 369 (227–598)
SDF1
rs1413519
GG 2562 (2513–2611) 0.225 338 (295–386) 0.300
CG 2588 (2522–2655) (0.222) 401 (335–482) (0.229)
CC 2725 (2541–2909) 397 (240–658)
CXCR4
rs16832740
AA 2557 (2509–2606) 0.424 374 (328–426) 0.878
AG 2556 (2487–2624) (0.747) 395 (329–475) (0.783)
GG 2863 (2501–2854) 370 (230–595)
CXCR4
rs12691874
AA 2514 (2437–2591) 0.306 414 (336–512) 0.272
AG 2588 (2534–2641) (0.600) 362 (313–419) (0.169)
GG 2571 (2488–2654) 322 (256–404)
SDF-1 levels and EPC numbers (per 1 ml blood) are age- and sex-adjusted
arithmetic (95%CI) and geometric means (95%CI), respectively. P values are
from general linear models adjusted for age and sex and in brackets from
models additionally adjusted for canditate vascular risk factors and
determinants of SDF-1a levels (LDL and HDL cholesterol [mg/dL], smoking [0,1],
hypertension [0,1], diabetes [0,1], alcohol consumption [gram/day],
homocystein [mmol/L], hsCRP [mg/L], MMP9 [ng/mL], cystatin C [mg/L],
fibrinogen [mg/dL]).
doi:10.1371/journal.pone.0004061.t003
Table 1. Association between SDF-1a level and selected vascular risk factors and laboratory parameters (2005).
Variable SDF-1a tertile group (pg/ml) P value for trend
Low Tertile (lower
than 2350)
Medium Tertile
(2350–2743)
High Tertile
(higher than 2743)
Alcohol consumption (g/day) 21.9627.4 17.9623.9 15.1624.5 0.042
Reticulocytes (%)1 2 . 7 63.42 12.263.30 11.763.15 0.002
MMP9 (ng/mL) 69.2660.6 80.5659.0 87.3660.2 0.001
High-sensitivity CRP (mg/L) 3.564.7 3.163.6 5.169.9 0.037
Fibrinogen (mg/dL) 285.4653.8 296.4654.2 311.4664.2 0.009
HOMOCYSTEIN (MMOL/L) 11.665.9 11.465.0 13.767.4 0.017
Cystatin C (mg/L) 0.9260.16 0.9860.23 1.1260.31 ,0.001
Values are means 6SD. P values for trend are from age- and sex-adjusted analyses.
doi:10.1371/journal.pone.0004061.t001
Table 2. Genotype and allele frequencies of SDF1 and CXCR4
SNPs studied
Gene SNP Genotype N (%) Allele Frequency
SDF1 rs2297630 GG 463 (60.05) G 0.78
AG 271 (35.15) A 0.22
AA 37 (4.80)
rs266085 GG 307 (42.05) G 0.63
AG 311 (42.60) A 0.37
AA 112 (15.34)
AG 351 (46.61) A 0.37
AA 104 (13.81)
rs1801157 GG 445 (62.94) G 0.79
AG 231 (32.67) A 0.21
AA 31 (4.38)
rs1413519 GG 462 (63.20) G 0.79
CG 238 (32.56) C 0.21
CC 31 (4.24)
CXCR4 rs16832740 AA 447 (62.34) A 0.79
AG 237 (33.05) G 0.21
GG 33 (4.60)
rs12691874 AA 189 (26.21) A 0.52
AG 371 (51.46) G 0.48
GG 161 (22.33)
doi:10.1371/journal.pone.0004061.t002
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mia[42], colorectal cancer[43], sporadic breast cancer[44], carotid
artery stenosis[45], type I diabetes[46] and systemic lupus
erythematosus[47]. However, in vitro experiments show that this
SNP (rs1801157) does not have a direct functional effect on SDF1
expression[48], raising the possibility that it may be a marker for a
functionalSNP at the SDF1 locus due to linkage disequilibrium. This
possibility is consistent with the fact that the SDF1 gene is
transcribed into two isoforms, SDF1a and SDF1b, and that the
rs1801157 SNP is located inthe39untranslated region ofthe SDF1b
transcript but not in the SDF1a transcript[49,50]. In the Bruneck
study cohort, we found that the rs2297630 SNP, but not the
rs266085 or rs1801157 SNP, was associated with SDF1a level and
EPC number. Taken together, the studies mentioned above and the
present study suggest that variation in SDF1 gene has an influence
on SDF1 levels. The populations examined in these different studies
may have different genetic structure and linkage disequilibrium
patterns, which may explain why different SDF1 SNPs were
associated with SDF1 levels in the different studies.
Some particular attentions should be drawn regarding our
findings. Firstly, the consideration of the nature of EPC is important,
since there is no a unique criteria for identification of EPC, yet.
Immenseattentionregardingthe definition ofEPChasrecentlybeen
drawn due to the fact that the characterization and function of EPC
isolated with different methodologies were quite different from each
other[51]. Myeloid PBMNC derived spindle like EPC, but not
circulating CD34+ cells was used to quantify the circulating EPC
number in our study. Although a positive relationship between them
was reported in the literature, the number of cultured EPC may not
always reflect the number of circulating CD34+ and/or KDR+
EPC. Secondly, many diseases have influence on the role of EPC
number, such as diabetes[10,11], smoking[12], rheumatoid arthri-
tis[13] or chronic renal failure[14], among them muchreduced EPC
number have been reported. Extensive adjustments for cardiovas-
cular risk factors and diseases have been conducted in our study to
exclude any potential influence on our findings. Finally, no
relationship or association between EPC-CFU and plasma SDF-
1a levels and SDF-1 gene SNPs were observed in our study, which
indicating that neither plasma SDF-1a levels nor SDF-1 SNP could
affect the proliferation and migration of EPC reflected by their
ability to form EPC colonies in the culture.
In summary, our data indicate that although the SDF1 level and
EPC number may both increase in response to acute ischaemic
events, the relationship between blood SDF1 level and EPC
number is complex and they are inversely correlated in the normal
situation as observed in the Bruneck study cohort which was
recruited from the general population. Our data also indicate that
circulating EPC number is influenced by variation in the SDF1
gene likely via an effect of the genetic variation on SDF1a
expression. These findings help understand the mechanisms
underlying the inter-individual variability in EPC number which
has an implication in the pathogenesis of atherosclerosis and other
cardiovascular diseases.
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Figure 2. Associations of the SDF1 rs2297630 SNP (2000) with EPC number (median and IQR, A) and blood SDF1a level (arithmetic
means and SD, B) assessed in the 2005 evaluation of the Bruneck Study.
doi:10.1371/journal.pone.0004061.g002
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